Cosmo Pharmaceuticals NV (LTS:0RGI) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Cosmo Pharmaceuticals NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cosmo Pharmaceuticals NV's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Cosmo Pharmaceuticals NV's long-term debt to total assets ratio declined from Jun. 2023 (0.00) to Jun. 2024 (0.00). It may suggest that Cosmo Pharmaceuticals NV is progressively becoming less dependent on debt to grow their business.

Cosmo Pharmaceuticals NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV LT-Debt-to-Total-Asset Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.28

0.21

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.22	-	-	-	-

Cosmo Pharmaceuticals NV LT-Debt-to-Total-Asset Calculation

Cosmo Pharmaceuticals NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.888	/	522.445
	=	0.00

Cosmo Pharmaceuticals NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	0.687	/	614.069
	=	0.00

Cosmo Pharmaceuticals NV (LTS:0RGI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cosmo Pharmaceuticals NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (LTS:0RGI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

COPNz:UK C43:Germany COPN:Switzerland

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV Headlines

No Headlines